New imaging comparison could improve prostate cancer monitoring
NCT ID NCT06461689
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study looked at 80 patients with advanced prostate cancer that had stopped responding to chemotherapy. All patients received a radioactive drug called 177Lu-PSMA-617. Researchers compared two types of scans—PET and SPECT—to see which better tracks changes in tumor size and activity over time. The goal is to find the best way to monitor how well the treatment is working.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
177Lu-PSMA-617 (a radioactive drug)
What this could lead to
If successful, this could help doctors choose the best imaging method to monitor treatment response in advanced prostate cancer.
What could go wrong
This is a small, completed study that only looks at imaging data, not patient outcomes. The results may not change current practice.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHRU de NANCY
Vandœuvre-lès-Nancy, 54511, France